VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes

Journal of Dental Research

Volumn 86, Issue 9, 2007, Pages 883-887

  Foster, N ^a,b   Andreadou, K ^a   Jamieson, L ^a   Preshaw, P M ^a   Taylor, J J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

IL 18; IL 18 BPa; LPS; Porphyromonas gingivalis; VIP

Indexed keywords

AUTACOID; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN-18 BINDING PROTEIN; LIPOPOLYSACCHARIDE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; MONOCYTE; PHYSIOLOGY; PORPHYROMONAS GINGIVALIS;

ANALYSIS OF VARIANCE; CELL LINE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; MONOCYTES; PORPHYROMONAS GINGIVALIS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34548730856     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910708600915     Document Type: Article

References (34)

1. Anderson EJ, McGrath MA, Thalhamer T, McInnes IB (2006). Interleukin-12 to interleukin 'infinity': the rationale for future therapeutic cytokine targeting. Springer Semin Immunopathol 27:425-442.
2. Dayer JM (1999). Interleukin-18, rheumatoid arthritis, and tissue destruction. J Clin Invest 104:1337-1339.
3. Delgado M, Ganea D (1999). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem 274:31930-31940.
4. Delgado M, Ganea D (2000). Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165:3051-3057.
5. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, et al. (1999a). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 162:1200-1205.
6. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999b). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162:1707-1716.
7. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999c). VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96:167-181.
8. Foster N, Cheetham J, Taylor JJ, Preshaw PM (2005). VIP inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J Dent Res 84:999-1004.
9. Foster N, Lea SR, Preshaw PM, Taylor JJ (2007). Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 81:893-903.
10. Gemmell E, Seymour GJ (2004). Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease. Periodontol 2000 35:21-41.
11. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, et al. (1997). Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619-623.
12. Gracie JA (2004). Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 136:402-404.
13. Gracie JA, Robertson SE, McInnes IB (2003). Interleukin-18. J Leukoc Biol 73:213-224.
14. Hurgin V, Novick D, Rubinstein M (2002). The promoter of IL-18 binding protein: activation by an IFN-gamma-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci USA 99:16957-16962.
15. Johnson RB, Serio FG (2005). Interleukin-18 concentrations and the pathogenesis of periodontal disease. J Periodontol 76:785-790.
16. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. (2000). Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 97:1190-1195.
17. Kitchens RL, Ulevitch RJ, Munford RS (1992). Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J Exp Med 176:485-494.
18. Kornman KS, Page RC, Tonetti MS (1997). The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000 14:33-53.
19. Lamont RJ, Jenkinson HF (1998). Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 62:1244-1263.
20. Linden GJ, Mullally BH, Burden DJ, Lamey PJ, Shaw C, Ardill J, et al. (2002). Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol 29:484-489.
21. Miranda LA, Fischer RG, Sztajnbok FR, Johansson A, Figueredo CM, Gustafsson A (2005). Increased interleukin-18 in patients with juvenile idiopathic arthritis and early attachment loss. J Periodontol 76:75-82.
22. Muhl H, Kampfer H, Bosmann M, Frank S, Radeke H, Pfeilschifter J (2000). Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun 267:960-963.
23. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T (1989). Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 57:590-595.
24. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (1999). Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-136.
25. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. (2001). A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334-342.
26. Orozco A, Gemmell E, Bickel M, Seymour GJ (2006). Interleukin-1 beta, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol Immunol 21:256-260.
27. Paulukat J, Bosmann M, Nold M, Garkisch S, Kampfer H, Frank S, et al. (2001). Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 167:7038-7043.
28. Pihlstrom BL, Michalowicz BS, Johnson NW (2005). Periodontal diseases. Lancet 366:1809-1820.
29. Pozo D, Delgado M (2004). The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 18:1325-1334.
30. Rouabhia M, Ross G, Page N, Chakir J (2002). Interleukin-18 and gamma interferon production by oral epithelial cells in response to exposure to Candida albicans or lipopolysaccharide stimulation. Infect Immun 70:7073-7080.
31. Seymour GJ, Taylor JJ (2004). Shouts and whispers: an introduction to immunoregulation in periodontal disease. Periodontol 2000 35:9-13.
32. Tardif F, Ross G, Rouabhia M (2004). Gingival and dermal fibroblasts produce interleukin-1 beta converting enzyme and interleukin-1 beta but not interleukin-18 even after stimulation with lipopolysaccharide. J Cell Physiol 198:125-132.
33. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. (1998). IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 161:3400-3407.
34. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, et al. (1999). IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 96:13962-13966.